# Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)

> **NCT04346277** · — · NO_LONGER_AVAILABLE · sponsor: **Implicit Bioscience**

## Conditions studied

- COVID
- ARDS, Human
- Ards
- SARS-CoV2

## Interventions

- **BIOLOGICAL:** IC14, a monoclonal antibody against CD14

## Key facts

- **NCT ID:** NCT04346277
- **Lead sponsor:** Implicit Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04346277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04346277, "Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04346277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*